Zacks: Innophos Holdings, Inc. (NASDAQ:IPHS) Given $46.00 Average Target Price by Brokerages

Innophos Holdings, Inc. (NASDAQ:IPHS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation. Innophos’ rating score has improved by 50% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokerages have set a one year consensus target price of $46.00 for the company and are expecting that the company will post $0.53 earnings per share for the current quarter, according to Zacks. Zacks has also given Innophos an industry rank of 220 out of 255 based on the ratings given to its competitors.

A number of equities analysts have commented on the stock. ValuEngine upgraded shares of Innophos from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. BidaskClub lowered shares of Innophos from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Finally, Zacks Investment Research upgraded shares of Innophos from a “sell” rating to a “hold” rating in a research note on Wednesday, October 9th.

Shares of IPHS stock opened at $32.16 on Wednesday. Innophos has a 12 month low of $22.57 and a 12 month high of $37.53. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.85 and a quick ratio of 1.41. The firm has a market capitalization of $631.06 million, a P/E ratio of 14.11 and a beta of 1.44. The company’s fifty day moving average price is $32.01 and its two-hundred day moving average price is $29.63.

Innophos (NASDAQ:IPHS) last issued its quarterly earnings data on Tuesday, August 6th. The specialty chemicals company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.06. Innophos had a net margin of 3.79% and a return on equity of 12.35%. The firm had revenue of $185.04 million for the quarter, compared to analyst estimates of $196.55 million. During the same quarter in the previous year, the business posted $0.55 EPS. The firm’s revenue was down 10.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Innophos will post 2.18 EPS for the current year.

Several institutional investors have recently modified their holdings of the company. WINTON GROUP Ltd grew its position in shares of Innophos by 47.2% in the second quarter. WINTON GROUP Ltd now owns 12,493 shares of the specialty chemicals company’s stock valued at $364,000 after purchasing an additional 4,008 shares in the last quarter. Confluence Investment Management LLC grew its position in shares of Innophos by 3.6% in the second quarter. Confluence Investment Management LLC now owns 150,168 shares of the specialty chemicals company’s stock valued at $4,371,000 after purchasing an additional 5,244 shares in the last quarter. Aperio Group LLC grew its position in shares of Innophos by 1.7% in the second quarter. Aperio Group LLC now owns 38,543 shares of the specialty chemicals company’s stock valued at $1,122,000 after purchasing an additional 652 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its position in shares of Innophos by 8.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 9,530 shares of the specialty chemicals company’s stock valued at $277,000 after purchasing an additional 710 shares in the last quarter. Finally, Wedge Capital Management L L P NC grew its position in shares of Innophos by 7.0% in the second quarter. Wedge Capital Management L L P NC now owns 7,318 shares of the specialty chemicals company’s stock valued at $213,000 after purchasing an additional 480 shares in the last quarter. Institutional investors and hedge funds own 93.65% of the company’s stock.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Recommended Story: What is a blue-chip stock?

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.